A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice.
Langat virus (LGT), the naturally attenuated member of the tick-borne encephalitis virus (TBEV) complex, was tested extensively in clinical trials as a live TBEV vaccine and was found to induce a protective, durable immune response; however, it retained a low residual neuroinvasiveness in mice and humans. In order to ablate or reduce this property, LGT mutants that produced a small plaque size or temperature-sensitive (ts) phenotype in Vero cells were generated using 5-fluorouracil. One of these ts mutants, clone E5-104, exhibited a more than 10(3)-fold reduction in replication at the permissive temperature in both mouse and human neuroblastoma cells and lacked detectable neuroinvasiveness for highly sensitive immunodeficient mice. The E5-104 mutant possessed five amino acid substitutions in the structural protein E and one change in each of the nonstructural proteins NS3 and NS5. Using reverse genetics, we demonstrated that a Lys(46)-->Glu substitution in NS3 as well as a single Lys(315)-->Glu change in E significantly impaired the growth of LGT in neuroblastoma cells and reduced its peripheral neurovirulence for SCID mice. This study and our previous experience with chimeric flaviviruses indicated that a decrease in viral replication in neuroblastoma cells might serve as a predictor of in vivo attenuation of the neurotropic flaviviruses. The combination of seven mutations identified in the nonneuroinvasive E5-104 mutant provided a useful foundation for further development of a live attenuated TBEV vaccine. An evaluation of the complete sequence of virus recovered from brain of SCID mice inoculated with LGT mutants identified sites in the LGT genome that promoted neurovirulence/neuroinvasiveness.
Rumyantsev
Alexander A
AA
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases/NIH, 12735 Twinbrook Parkway, Twinbrook 3, Room 3W13, MSC 8133, Bethesda, MD 20892-8133, USA.
Murphy
Brian R
BR
Pletnev
Alexander G
AG
D000818:Animals; D001921:Brain / Q000821:virology; D045744:Cell Line, Tumor; D002522:Chlorocebus aethiops; D004669:Encephalitis Viruses, Tick-Borne / Q000235:genetics* / Q000276:immunology / Q000472:pathogenicity* / Q000502:physiology; D004675:Encephalitis, Tick-Borne / Q000276:immunology / Q000821:virology; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D008958:Models, Molecular; D016296:Mutagenesis; D009154:Mutation; D009447:Neuroblastoma / Q000821:virology; D010641:Phenotype; D011487:Protein Conformation; D013696:Temperature; D014613:Vaccines, Attenuated / Q000235:genetics; D014709:Vero Cells; D014759:Viral Envelope Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000235:genetics; D014774:Virulence / Q000235:genetics; D014779:Virus Replication
D014613:Vaccines, Attenuated; D014759:Viral Envelope Proteins; D014765:Viral Vaccines